Autophagy — the first escape route

Autophagy is the cell's internal recycling system.

It breaks down damaged parts and reuses them as fuel or building blocks.

Under stress, that can become a survival advantage.

That is why it keeps showing up in treatment-resistant cancer biology.

Why autophagy matters here

In ER-positive breast cancer, antiestrogen pressure can leave cells short on energy.

Autophagy helps them cope.

Instead of dying, they recycle.

That can turn treatment stress into survival time.

McGrath et al. (2024) argue that this is often cytoprotective autophagy.

In plain language, that means autophagy is helping cancer cells stay alive.

The form that matters most

McGrath et al. (2024) focus on macroautophagy.

This is the version where the cell builds a membrane pouch, loads cargo into it, and fuses that pouch with a lysosome for breakdown.

The steps are:

1. initiation

2. elongation

3. autophagosome closure

4. fusion with the lysosome

Each step can become a drug target in theory.

The control system above it

A major regulator is mTOR.

When nutrients look plentiful, mTOR suppresses autophagy.

When stress rises, that brake comes off.

The authors also highlight an energy-stress pathway involving AMPK, mTORC2, and AKT.

This matters because it helps explain how cells can stay alive even when ATP is low.

In other words, treatment can stress the cell hard enough to trigger autophagy, but not hard enough to force death.

What researchers measure

Two common markers are:

• LC3-II

• p62 / SQSTM1

These markers help show whether autophagy is active.

They do not answer the full question by themselves.

Researchers usually want to know autophagic flux.

That means whether the whole pathway is actually moving.

What the ER-positive evidence shows

Across tamoxifen, fulvestrant, and aromatase-inhibitor models, a similar pattern appears.

Cells exposed to ongoing antiestrogen pressure often increase autophagy as resistance develops.

Blocking autophagy in those models can restore cell death.

McGrath et al. (2024) highlight a few recurring signals:

• GLUT1 overexpression in tamoxifen-resistant cells

• GRP78 upregulation in autophagy-linked resistance

• protective autophagy after endocrine or CDK4/6 pressure

It also points to isoform-specific AMPK biology.

AMPKα1 looks more tied to cell death.

AMPKα2 looks more tied to survival autophagy.

That split may matter later for more selective targeting.

The hydroxychloroquine question

At the moment, chloroquine and hydroxychloroquine are the main approved drugs used to block autophagy in clinical research.

They work late in the pathway.

They raise lysosomal pH and disrupt final cargo digestion.

That is a practical advantage.

It is also a limit.

These drugs are not clean, precise autophagy tools.

They bring off-target effects and dose limits.

The authors still treat them as the main current bridge into the clinic.

Why timing may matter more than the drug itself

One of the most important points in McGrath et al. (2024) is about sequence.

If a treatment first induces autophagy, an autophagy blocker may work best after that state has been triggered.

That is different from giving both drugs casually at the same time without a clear logic.

Ongoing trials are testing versions of this idea with endocrine therapy and CDK4/6 inhibitors.

Bottom line

Autophagy is not just a background process in this review.

It is one of the main ways ER-positive cancer cells may survive endocrine and CDK4/6 pressure.

That makes it an appealing target.

The challenge is hitting it hard enough, at the right time, without adding too much toxicity.